This study is a Phase 3, multi-center, randomized, 6-week, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of solriamfetol in children aged 6 to <12 years with ADHD.
Inclusion Criteria:
Exclusion Criteria:
akim@axsome.com929-618-4421
Up to 6 weeks
Up to 6 weeks
Up to 6 weeks
A Study to Assess the Efficacy and Safety of Solriamfetol in Adolescents With ADHD
A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)
A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults
Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol
A Trial of Solriamfetol in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
Efficacy and Tolerance of Solriamfetol in Patients Affected with Idiopathic Hypersomnia.